UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C

Journal of Virology

Volumn 86, Issue 9, 2012, Pages 4989-4999

  Mufhandu, Hazel T ^a   Gray, Elin S ^b   Madiga, Maphuti C ^b   Tumba, Nancy ^b   Alexandre, Kabamba B ^b   Khoza, Thandeka ^a   Wibmer, Constantinos Kurt ^b   Moore, Penny L ^b   Morris, Lynn ^b,c   Khati, Makobetsa ^a,d  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; IGG1B12 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UCLA 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; CELL VIABILITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ENTRY; VIRUS NEUTRALIZATION;

APTAMERS, NUCLEOTIDE; BINDING SITES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; NEUTRALIZATION TESTS; POINT MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861309127     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06893-11     Document Type: Article

References (59)

1. Alexandre KB, et al. 2010. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, griffithsin, cyanovirin-N and scytovirin. Virology 402:187-196.
2. Alexandre KB, et al. 2011. Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J. Virol. 85:9039-9050.
3. Alkhatib G, et al. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
4. Atchison RE, et al. 1996. Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science 274: 1924-1926.
5. Binley JM, et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
6. Bures R, et al. 2000. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 16:2019-2035.
7. Castanotto D, Rossi JJ. 2009. The promises and pitfalls of RNAinterference- based therapeutics. Nature 457:426-433.
8. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
9. Cilliers T, et al. 2003. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. 77:4449-4456.
10. Cohen C, et al. 2008. An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 381: 46-54.
11. Cormier EG, Tran DN, Yukhayeva L, Olson WC, Dragic T. 2001. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 75:5541-5549.
12. Decker JM, et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
13. Dey AK, Griffiths C, Lea SM, James W. 2005. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 11:873-884.
14. Dey AK, et al. 2005. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol. 79:13806-13810.
15. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822.
16. Fenyo EM, et al. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4:e4505.
17. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. 2006. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 3:e255.
18. Gray ES, et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81:6187-6196.
19. Gray ES, Moore PL, Pantophlet RA, Morris L. 2007. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J. Virol. 81: 10769-10776.
20. Gray ES, et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83:8925-8937.
21. Honnen WJ, et al. 2007. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 81:1424-1432.
22. Jacobson JM, et al. 2000. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182:326-329.
23. Joubert MK, et al. 2010. A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization. Biochemistry 49:5880-5890.
24. Keefe AD, Pai S, Ellington A. 2010. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9:537-550.
25. Khati M, et al. 2003. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2=FRNA aptamers. J. Virol. 77:12692-12698.
26. Kothe DL, et al. 2006. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352:438-449.
27. Kwong PD, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
28. Kwong PD, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
29. Lalezari JP, et al. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drugresistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
30. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine- elicited neutralizing antibodies. J. Virol. 79:10108-10125.
31. Li M, et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776-11790.
32. Li Y, et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
33. Lopes de Campos WR, Coopusamy D, Morris L, Mayosi BM, Khati M. 2009. Cytotoxicological analysis of a gp120 binding aptamer with crossclade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob. Agents Chemother. 53:3056-3064.
34. Montefiori DC. 2004. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assay, vol 12. John Wiley, Hoboken, NJ.
35. Moore JP, Doms RW. 2003. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U. S. A. 100:10598-10602.
36. Moore MD, et al. 2011. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J. Biol. Chem. 286:2526-2535.
37. Nagashima KA, et al. 2001. Human immunodeficiency virus type 1 entry inhibitorsPRO542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183:1121-1125.
38. O'Sullivan CK. 2002. Aptasensors-the future of biosensing? Anal. Bioanal Chem. 372:44-48.
39. Osztie E, et al. 2001. Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV cytoxan chemotherapy for progressive optichypothalamic gliomas in young children. AJNR Am. J. Neuroradiol. 22: 818-823.
40. Pantophlet R, et al. 2003. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77:642-658.
41. Pinter A, et al. 2005. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J. Virol. 79:6909-6917.
42. Rizzuto C, Sodroski J. 2000. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 16:741-749.
43. Rizzuto CD, et al. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
44. Sayer N, Ibrahim J, Turner K, Tahiri-Alaoui A, James W. 2002. Structural characterization of a 2=F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. Biochem. Biophys. Res. Commun. 293:924-931.
45. Schols D. 2006. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 71:216-226.
46. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. 2000. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune Defic. Syndr. 25:99-102.
47. Van Harmelen JH, et al. 1999. A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res. Hum. Retroviruses 15:395-398.
48. Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
49. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
50. Wang W, Jia L-Y. 2009. Progress in aptamer screening methods. Chin. J. Anal. Chem. 37:454-460.
51. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
52. Wyatt R, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
53. Zhou J, Li H, Li S, Zaia J, Rossi JJ. 2008. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 16:1481-1489.
54. Zhou J, Rossi JJ. 2010. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21:1-10.
55. Zhou J, Shu Y, Guo P, Smith DD, Rossi JJ. 2011. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 54:284-294.
56. Zhou J, et al. 2009. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 37:3094-3109.
57. Zhou T, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
58. Zwick MB, et al. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79:1252-1261.
59. Zwick MB, et al. 2001. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75:12198-12208.